Modulation of telomere length in telomerase positive cells and cancer therapy
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 22, 2010
Grant Date -
Jan 22, 2009
app pub date -
Mar 27, 2006
filing date -
Mar 25, 2005
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Induction of telomere shortening, G2 arrest and apoptosis in telomerase positive cancer cells using acyclic nucleoside analogs has been disclosed. In addition, methods for impairment or prevention of tumorigenic telomerase positive cells from having a chance to grow into a tumor and methods for promoting tumor regression (decrease in size of an established tumor) using acyclic nucleoside analogs has been disclosed.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully